MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis Research

Background:

• The role of MYC in cancer metastasis remains controversial.
• Omomyc, a dominant-negative MYC inhibitor, has shown broad antitumor activity.
• Therapeutic efficacy of Omomyc against metastasis requires further investigation.

Purpose of the Study:

• To investigate the antimetastatic efficacy of MYC inhibition using Omomyc in breast cancer.
• To evaluate the therapeutic potential of Omomyc in various breast cancer subtypes, including triple-negative breast cancer.
• To assess the clinical applicability of pharmacologic Omomyc treatment for metastatic breast cancer.

Main Methods:

• Utilized transgenic Omomyc expression in preclinical breast cancer models.
• Administered pharmacologic treatment with recombinantly produced Omomyc miniprotein.
• Evaluated antimetastatic properties both in vitro and in vivo across different breast cancer molecular subtypes.

Main Results:

• MYC inhibition by Omomyc demonstrated efficacy across all breast cancer molecular subtypes.
• Omomyc displayed significant potent antimetastatic properties in vitro and in vivo.
• Pharmacologic Omomyc treatment recapitulated key features of transgenic expression, confirming clinical applicability.

Conclusions:

• MYC inhibition by Omomyc is effective against breast cancer metastasis, including triple-negative subtypes.
• Pharmacologic Omomyc miniprotein shows clinical potential for treating metastatic breast cancer.
• Omomyc represents a promising therapeutic strategy for advanced and metastatic breast cancer.